

Andrew Harkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2267085/publications.pdf>

Version: 2024-02-01

122
papers

4,856
citations

76326

40
h-index

106344

65
g-index

143
all docs

143
docs citations

143
times ranked

6480
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute neuroinflammation, sickness behavior and working memory responses to acute systemic LPS challenge following noradrenergic lesion in mice. <i>Brain, Behavior, and Immunity</i> , 2021, 94, 357-368.	4.1	22
2	Amygdala substructure volumes in Major Depressive Disorder. <i>NeuroImage: Clinical</i> , 2021, 31, 102781.	2.7	26
3	Kynurenic Acid Protects Against Reactive Glial-associated Reductions in the Complexity of Primary Cortical Neurons. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 679-692.	4.1	2
4	PBMC telomerase activity in depression and the response to electroconvulsive therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1297-1307.	3.2	1
5	Pharmacological targeting of β -adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease. <i>British Journal of Pharmacology</i> , 2020, 177, 282-297.	5.4	31
6	Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy. <i>Brain, Behavior, and Immunity</i> , 2020, 83, 153-162.	4.1	33
7	Dexamethasone attenuates inflammatory-mediated suppression of β -adrenoceptor expression in rat primary mixed glia. <i>Journal of Neuroimmunology</i> , 2020, 338, 577082.	2.3	8
8	Blood plasma B vitamins in depression and the therapeutic response to electroconvulsive therapy. <i>Brain, Behavior, & Immunity - Health</i> , 2020, 4, 100063.	2.5	12
9	Regulation of β -adrenoceptors in brain glia: implications for neuroinflammatory and degenerative disorders. <i>Neural Regeneration Research</i> , 2020, 15, 2035.	3.0	3
10	Persistent central inflammation and region specific cellular activation accompany depression- and anxiety-like behaviours during the resolution phase of experimental colitis. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 616-632.	4.1	35
11	Ketamine Versus Midazolam for Depression Relapse Prevention Following Successful Electroconvulsive Therapy. <i>Journal of ECT</i> , 2019, 35, 115-121.	0.6	13
12	L- α -amino adipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats. <i>Journal of Neuroscience Research</i> , 2019, 97, 804-816.	2.9	12
13	A gut instinct for kynurenic acid. <i>Brain, Behavior, and Immunity</i> , 2019, 79, 16-17.	4.1	0
14	L-alpha-amino adipic acid provokes depression-like behaviour and a stress related increase in dendritic spine density in the pre-limbic cortex and hippocampus in rodents. <i>Behavioural Brain Research</i> , 2019, 362, 90-102.	2.2	17
15	Ketamine and depression: A special case for kynurenic acid?. <i>Brain, Behavior, and Immunity</i> , 2019, 75, 10-11.	4.1	0
16	Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the β -adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease. <i>Brain, Behavior, and Immunity</i> , 2018, 69, 456-469.	4.1	21
17	The β -adrenoceptor agonist clenbuterol reduces the neuroinflammatory response, neutrophil infiltration and apoptosis following intra-striatal IL-1 β administration to rats. <i>Immunopharmacology and Immunotoxicology</i> , 2018, 40, 99-106.	2.4	14
18	Gut's "brain actions" underlying comorbid anxiety and depression associated with inflammatory bowel disease. <i>Acta Neuropsychiatrica</i> , 2018, 30, 275-296.	2.1	118

#	ARTICLE	IF	CITATIONS
19	Inhibitors of the NMDA-Nitric Oxide Signaling Pathway Protect Against Neuronal Atrophy and Synapse Loss Provoked by l-alpha Amino adipic Acid-treated Astrocytes. <i>Neuroscience</i> , 2018, 392, 38-56.	2.3	5
20	Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. <i>Psychoneuroendocrinology</i> , 2018, 95, 8-17.	2.7	69
21	DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to early life emotional abuse. <i>Psychiatry Research</i> , 2018, 265, 341-348.	3.3	120
22	Targeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's disease. <i>Neural Regeneration Research</i> , 2018, 13, 1332.	3.0	33
23	Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders. <i>Neuropharmacology</i> , 2017, 112, 307-323.	4.1	105
24	Association between psychological measures with inflammatory and disease-related markers of inflammatory bowel disease. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 221-230.	2.4	28
25	Regional Specific Modulation of Stress-Induced Neuronal Activation Associated with the PSD95/NOS Interaction Inhibitor ZL006 in the Wistar Kyoto Rat. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 833-843.	2.1	8
26	Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons. <i>European Journal of Pharmacology</i> , 2017, 810, 163-173.	3.5	25
27	Regional specific modulation of neuronal activation associated with nitric oxide synthase inhibitors in an animal model of antidepressant activity. <i>Behavioural Brain Research</i> , 2017, 316, 18-28.	2.2	13
28	Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2226.	4.1	49
29	Recent Advances in Translational Magnetic Resonance Imaging in Animal Models of Stress and Depression. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 150.	3.7	17
30	Editorial: Biology of Brain Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 366.	3.7	2
31	Novel Targets in the Glutamate and Nitric Oxide Neurotransmitter Systems for the Treatment of Depression. , 2016, , 81-113.		6
32	Clenbuterol activates the central IL-1 system via the β_2 -adrenoceptor without provoking inflammatory response related behaviours in rats. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 114-129.	4.1	8
33	P.4.011 L-tryptophan provokes a reduction of astrocytes in the prelimbic cortex and depressive-like behaviour in mice. <i>European Neuropsychopharmacology</i> , 2016, 26, S94-S95.	0.7	0
34	Amitriptyline protects against TNF α -induced atrophy and reduction in synaptic markers via a TrkA-dependent mechanism. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00195.	2.4	14
35	Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice. <i>NeuroImmunoModulation</i> , 2016, 23, 137-150.	1.8	12
36	Evaluation of NMDA signalling modifiers as putative antidepressants in animal models. <i>European Neuropsychopharmacology</i> , 2016, 26, S120.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Association of maternal emotional abuse with decreased serotonin transporter gene (SLC6A4) methylation. <i>European Neuropsychopharmacology</i> , 2016, 26, S177.	0.7	2
38	Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial). <i>Pilot and Feasibility Studies</i> , 2016, 2, 38.	1.2	3
39	Glial fibrillary acidic protein (GFAP) immunoreactivity correlates with cortical perfusion parameters determined by bolus tracking arterial spin labelling (bt-ASL) magnetic resonance (MR) imaging in the Wistar Kyoto rat. <i>Physiology and Behavior</i> , 2016, 160, 66-79.	2.1	20
40	Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1688-1699.	5.6	45
41	Stress-Related Immune Markers in Depression: Implications for Treatment. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw001.	2.1	53
42	P.1.f.015 Evidence for central molecular changes and changes to neuronal activity in an animal model of inflammatory bowel disease. <i>European Neuropsychopharmacology</i> , 2015, 25, S233-S234.	0.7	0
43	Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1. <i>Frontiers in Neuroscience</i> , 2015, 9, 428.	2.8	27
44	Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. <i>Brain, Behavior, and Immunity</i> , 2015, 48, 274-286.	4.1	70
45	Small-molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuronal atrophy in primary cortical neurons. <i>Neuroscience</i> , 2015, 301, 421-438.	2.3	10
46	Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI. <i>Psychopharmacology</i> , 2015, 232, 1501-1513.	3.1	4
47	P.1.d.002 A role for glial-associated kynurenine pathway activation in modulating neuronal outgrowth and complexity. <i>European Neuropsychopharmacology</i> , 2015, 25, S206-S207.	0.7	1
48	Rodent Models of Stress-Induced Depression: The Link Between Stress and Immune System Related Changes. <i>Current Topics in Neurotoxicity</i> , 2015, , 33-62.	0.4	3
49	Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1477-1486.	2.1	19
50	Expression of glucocorticoid inducible genes is associated with reductions in cornu ammonis and dentate gyrus volumes in patients with major depressive disorder. <i>Development and Psychopathology</i> , 2014, 26, 1209-1217.	2.3	19
51	Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 917-928.	2.1	76
52	Muscling In on Depression. <i>New England Journal of Medicine</i> , 2014, 371, 2333-2334.	27.0	14
53	Noradrenaline acting on astrocytic α_2 -adrenoceptors induces neurite outgrowth in primary cortical neurons. <i>Neuropharmacology</i> , 2014, 77, 234-248.	4.1	44
54	The anti-inflammatory actions of noradrenergic agents as a target to prevent neurodegeneration in Parkinson's disease. <i>Journal of Neuroimmunology</i> , 2014, 275, 122-123.	2.3	1

#	ARTICLE	IF	CITATIONS
55	Noradrenaline-mediated protection against TNF-alpha-induced neuronal atrophy. Journal of Neuroimmunology, 2014, 275, 167.	2.3	1
56	Astrocytic dysfunction induced by l-alphaaminoadipic acid reduces measures of neuronal complexity in vitro; rescue by NMDA receptor antagonists. Journal of Neuroimmunology, 2014, 275, 127-128.	2.3	0
57	Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulbectomised rat model of depression. European Neuropsychopharmacology, 2014, 24, 1349-1361.	0.7	22
58	AB0186...Elevated Indoleamine-2,3-Dioxygenase (IDO) and Tryptophan Catabolism in Primary Sjögren's Syndrome Patients, Positive for the Interferon Type I Signature: A Possible Link to Fatigue and Depression. Annals of the Rheumatic Diseases, 2014, 73, 864.2-864.	0.9	1
59	Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology, 2013, 228, 157-166.	3.1	149
60	Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain, Behavior, and Immunity, 2013, 28, 170-181.	4.1	173
61	C-reactive protein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy. Brain, Behavior, and Immunity, 2013, 34, 108-119.	4.1	81
62	Stimulation of central Î²2-adrenoceptors suppresses NFÎ±B activity in rat brain: A role for Î±B. Neurochemistry International, 2013, 63, 368-378.	3.8	22
63	Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice. Neuropsychopharmacology, 2013, 38, 1575-1584.	5.4	65
64	<sc>MDMA</sc> - ecstasy™ increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (<sc>ASL</sc>) <sc>MRI</sc>. British Journal of Pharmacology, 2013, 169, 974-987.	5.4	6
65	The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. Journal of Leukocyte Biology, 2012, 92, 959-975.	3.3	293
66	Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, ecstasy™) and related psychostimulants: mechanisms and mediators. British Journal of Pharmacology, 2012, 167, 946-959.	5.4	52
67	Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain, Behavior, and Immunity, 2012, 26, 979-987.	4.1	90
68	Dopamine D₁ Receptor-Mediated Intracellular Responses in the Hypothalamus after Co-Administration of Caffeine with MDMA. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 283-289.	2.5	6
69	The PSD-95/nNOS complex: New drugs for depression?. , 2012, 133, 218-229.		68
70	The effect of antidepressants on inflammatory markers in animal models of depression. European Psychiatry, 2011, 26, 2091-2091.	0.2	0
71	Comparison of kynurenine pathway activation and tryptophan depletion induced by activation of human T-cells and innate immune cells. Brain, Behavior, and Immunity, 2011, 25, S208-S209.	4.1	1
72	149. Poly I:C-induced activation of the innate immune response is accompanied by symptoms of depression and anxiety. Brain, Behavior, and Immunity, 2011, 25, S222.	4.1	0

#	ARTICLE	IF	CITATIONS
73	150. Stimulation of central \hat{I}^2 -adrenoceptors suppresses NF- \hat{I}^B activity in hippocampus and cortex: A role for \hat{I}^B . <i>Brain, Behavior, and Immunity</i> , 2011, 25, S222.	4.1	0
74	A role for adenosine A1 receptor blockade in the ability of caffeine to promote MDMA \hat{I}^B -induced striatal dopamine release. <i>European Journal of Pharmacology</i> , 2011, 650, 220-228.	3.5	19
75	Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA (\hat{I}^B -ecstasy \hat{I}^B). <i>Psychopharmacology</i> , 2010, 211, 15-25.	3.1	20
76	Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. <i>Journal of Neuroimmunology</i> , 2010, 220, 34-42.	2.3	57
77	A role for serotonin in the antidepressant activity of NG-Nitro-L-arginine, in the rat forced swimming test. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 94, 524-533.	2.9	31
78	Mechanisms mediating the ability of caffeine to influence MDMA (\hat{I}^B -Ecstasy \hat{I}^B) \hat{I}^B -induced hyperthermia in rats. <i>British Journal of Pharmacology</i> , 2010, 160, 860-877.	5.4	36
79	Noradrenaline acting at central \hat{I}^2 -adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: Implications for neurodegeneration. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 660-671.	4.1	58
80	The \hat{I}^2 -adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity. <i>Brain, Behavior, and Immunity</i> , 2010, 24, 1354-1361.	4.1	56
81	A role for central IL-1beta in the suppression of locomotor activity induced the by the beta2-adrenoceptor agonist clenbuterol?. <i>Brain, Behavior, and Immunity</i> , 2010, 24, S2-S3.	4.1	0
82	The NOD mouse model for immune induced depressive-like behavior. <i>Brain, Behavior, and Immunity</i> , 2010, 24, S50-S51.	4.1	0
83	Noradrenaline acting at \hat{I}^2 -adrenoceptors induces expression of IL-1 \hat{I}^2 and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. <i>Neuropharmacology</i> , 2010, 59, 37-48.	4.1	72
84	Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 687.	2.1	122
85	47. Noradrenaline re-uptake inhibition influences neuroinflammatory and degenerative changes associated with the excitotoxin kainic acid. <i>Brain, Behavior, and Immunity</i> , 2009, 23, S38.	4.1	0
86	107. A systemic LPS challenge does not alter central Beta2-adrenoceptor expression or responsiveness. <i>Brain, Behavior, and Immunity</i> , 2009, 23, S54-S55.	4.1	0
87	Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN- \hat{I}^3 ?. <i>Neuroscience Letters</i> , 2008, 441, 29-34.	2.1	180
88	Reduced efficacy of fluoxetine following MDMA (\hat{I}^B -Ecstasy \hat{I}^B)-induced serotonin loss in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1894-1901.	4.8	16
89	Chronic Fluoxetine Treatment Attenuates Stressor-Induced Changes in Temperature, Heart Rate, and Neuronal Activation in the Olfactory Bulbectomized Rat. <i>Neuropsychopharmacology</i> , 2007, 32, 1312-1320.	5.4	68
90	Lipids and essential fatty acids in patients presenting with self-harm. <i>British Journal of Psychiatry</i> , 2007, 190, 112-117.	2.8	75

#	ARTICLE	IF	CITATIONS
91	Caffeine induces a profound and persistent tachycardia in response to MDMA (‘Ecstasy’) administration. <i>European Journal of Pharmacology</i> , 2007, 555, 194-198.	3.5	24
92	Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (‘Ecstasy’) and MDA (‘Love’). <i>Neuropharmacology</i> , 2006, 50, 69-80. ^{4.1}	4.1	56
93	Acute stress suppresses pro-inflammatory cytokines TNF- α and IL-1 β independent of a catecholamine-driven increase in IL-10 production. <i>Journal of Neuroimmunology</i> , 2005, 159, 119-128.	2.3	70
94	Methylenedioxymethamphetamine Suppresses Production of the Proinflammatory Cytokine Tumor Necrosis Factor- α Independent of a β -Adrenoceptor-Mediated Increase in Interleukin-10. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 134-143.	2.5	32
95	Olfactory bulbectomy in mice induces alterations in exploratory behavior. <i>Neuroscience Letters</i> , 2005, 374, 142-146.	2.1	85
96	Adenosine A1 Receptor Blockade Mimics Caffeine's Attenuation of Ethanol-Induced Motor Incoordination. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 95, 299-304.	2.5	32
97	Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. <i>European Neuropsychopharmacology</i> , 2004, 14, 274-281.	0.7	148
98	A review of the relevance and validity of olfactory bulbectomy as a model of depression. <i>Clinical Neuroscience Research</i> , 2003, 3, 253-262.	0.8	91
99	Methylenedioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine. <i>European Journal of Neuroscience</i> , 2003, 18, 1021-1027.	2.6	21
100	Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. <i>Neuropharmacology</i> , 2003, 44, 616-623.	4.1	137
101	A Toxicokinetic Study of Nickel-Induced Immunosuppression in Rats. <i>Immunopharmacology and Immunotoxicology</i> , 2003, 25, 655-670.	2.4	17
102	A combined and comparative study of physiologic and behavioral parameters in a systemic toxicity test. <i>Contemporary Topics in Laboratory Animal Science</i> , 2003, 42, 31-8.	0.2	0
103	A study of VitalView [®] for behavioural and physiological monitoring in laboratory rats. <i>Physiology and Behavior</i> , 2002, 77, 65-77.	2.1	54
104	Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine. <i>Journal of Psychopharmacology</i> , 2002, 16, 115-123.	4.0	85
105	Physiological and behavioral responses to stress: what does a rat find stressful?. <i>Lab Animal</i> , 2002, 31, 42-50.	0.4	18
106	Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviors in rats. <i>Life Sciences</i> , 2001, 68, 1367-1382.	4.3	33
107	Modulation of MK-801-induced behaviour by noradrenergic agents in mice. <i>Psychopharmacology</i> , 2001, 154, 177-188.	3.1	31
108	Methylenedioxymethamphetamine-induced suppression of interleukin-1 β and tumour necrosis factor- α is not mediated by serotonin. <i>European Journal of Pharmacology</i> , 2001, 418, 147-152.	3.5	23

#	ARTICLE	IF	CITATIONS
109	Olfactory Bulbectomy Provokes a Suppression of Interleukin-1 β and Tumour Necrosis Factor- α Production in Response to an in vivo Challenge with Lipopolysaccharide: Effect of Chronic Desipramine Treatment. <i>NeuroImmunoModulation</i> , 2000, 7, 27-35.	1.8	79
110	Effect of Subchronic Antidepressant Treatments on Behavioral, Neurochemical, and Endocrine Changes in the Forced-Swim Test. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 65, 591-597.	2.9	86
111	Test Conditions Influence the Response to a Drug Challenge in Rodents. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 65, 389-398.	2.9	19
112	Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors. <i>European Journal of Pharmacology</i> , 2000, 389, 187-192.	3.5	8
113	Characterization of d-fenfluramine-induced hypothermia: evidence for multiple sites of action. <i>European Journal of Pharmacology</i> , 2000, 390, 275-285.	3.5	36
114	Corrigendum to: "Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors" [Eur. J. Pharmacol. 389 (2000) 187-192]. <i>European Journal of Pharmacology</i> , 2000, 397, 399.	3.5	2
115	Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and β 1-adrenergic receptors in an animal model of depression. <i>Journal of Neural Transmission</i> , 2000, 107, 1213-1227.	2.8	19
116	Varying responses to the rat forced-swim test under diurnal and nocturnal conditions. <i>Physiology and Behavior</i> , 2000, 69, 531-539.	2.1	80
117	Metyrapone displays antidepressant-like properties in preclinical paradigms. <i>Psychopharmacology</i> , 1999, 145, 303-308.	3.1	42
118	Nitric oxide synthase inhibitors have antidepressant-like properties in mice. <i>European Journal of Pharmacology</i> , 1999, 372, 207-213.	3.5	202
119	Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. <i>European Journal of Pharmacology</i> , 1999, 379, 125-133.	3.5	54
120	Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity. <i>European Neuropsychopharmacology</i> , 1999, 9, 165-170.	0.7	26
121	Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. <i>European Journal of Pharmacology</i> , 1999, 364, 123-132.	3.5	85
122	The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment. <i>European Journal of Pharmacology</i> , 1998, 346, 15-21.	3.5	13